merp program & medication safety

39
MERP Program & Medication Safety July 23, 2010 Loriann De Martini, Pharm.D. Chief Pharmaceutical Consultant Center for Healthcare Quality

Upload: lucius

Post on 19-Jan-2016

215 views

Category:

Documents


3 download

DESCRIPTION

MERP Program & Medication Safety. July 23, 2010. Loriann De Martini, Pharm.D. Chief Pharmaceutical Consultant Center for Healthcare Quality. Presentation Outline. MERP Program Survey Process Survey Activities Survey Findings Administrative Penalties & Medication Safety - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: MERP Program & Medication Safety

MERP Program&

Medication Safety

July 23, 2010

Loriann De Martini, Pharm.D.Chief Pharmaceutical Consultant Center for Healthcare Quality

Page 2: MERP Program & Medication Safety

Presentation Outline

• MERP Program Survey Process Survey Activities Survey Findings

• Administrative Penalties & Medication Safety

• Medication Safety System Vulnerabilities

Page 3: MERP Program & Medication Safety

MERP Survey Process

• Surveys are triennial • Managed by CDPH Pharmaceutical Consultant

Unit • Approximately 32 hospitals/quarter• Outcome(s):

No deficiencies Deficiencies noted under Health and Safety (H&S) Code

and/or California Code of Regulations, Title 22. State Immediate Jeopardy finding. Federal Complaint Validation survey with deficiencies

noted under 42 Code of Federal Regulations with or without Condition Level deficiencies.

Federal Immediate Jeopardy finding Failure to report an Adverse Event

Page 4: MERP Program & Medication Safety

4

Failure to Report

•The Department may assess a hospital a civil penalty of $100 per day for each day that a facility does not report an adverse event timely.

•Medication Related AEs: Patient death or serious disability Associated with a medication error Directly related to hypoglycemia Associated with the use of a contaminated drug,

device, or biologic provided by the health facility Associated with use or function of a device in

patient care in which the device is used or functions other than as intended.

Page 5: MERP Program & Medication Safety

Serious Disability

Means a physical or mental impairment that substantially limits one or more of the major life activities of an individual, or the loss of bodily function, if the impairment or loss lasts more than seven days or is still present at the time of discharge from an inpatient health care facility, or the loss of a body part. [Health and Safety Code 1279.1(d)]

Page 6: MERP Program & Medication Safety

MERP Survey

• CDPH issued guidance – All Facilities Letters (AFL): AFL 08-39: Guidance on MERP survey process AFL 09-31: Establishes MERP email address to

address questions about the survey process: [email protected]

• CDPH AFLs http://www.cdph.ca.gov/certlic/facilities/Pages/LnCAFL.aspx

Page 7: MERP Program & Medication Safety

All Facilities Letter (AFL)

• Beginning July 1, 2010, L&C will begin distributing AFLs electronically using the following two methods: L&C’s Website and the California Health Alert Network (CAHAN) system. (AFL 10-06 4/2/10)

• L&C AFL website: http://www.cdph.ca.gov/certlic/facilities/Pages/LnCAFL.aspx

Page 8: MERP Program & Medication Safety

CAHAN

• California Health Alert Network (CAHAN). Each state is required to have a health alert

network. CDPH implemented CAHAN in 2003 It’s the state’s official public health emergency alerting system.

Voluntary For further information contact either your

County CAHAN Health Alert Network Coordinator, or contact CAHAN directly at the following contact points.Email: [email protected] Toll free phone number: 1-877-376-4767

Page 9: MERP Program & Medication Safety

MERP Survey Activities

• Off site: MERP file and License review• On site

Entrance conference Document request MERP facility questionnaire Clinical record review Medication storage assessment Medication pass observation Review medication error reports

• Exit Conference

Page 10: MERP Program & Medication Safety

Entrance Conference

• Document Request (attachment A)

• MERP Survey Facility Questionnaire (attachment B)

• MERP Survey Evaluation (attachment C)

Voluntary Mailed to Chief Can be anonymous Likert scale

Page 11: MERP Program & Medication Safety

Entrance Conference – Document Request

• P&Ps related to med errors, administration times, emergency med use

• List of patients in last three months PCA delivered medications Fentanyl transdermal Droperidol Insulin drip Reversal agents (Narcan, D50W, glucagon, Vit

K, protamine, flumazenil)

• Current MERP and evidence of annual reviews

Page 12: MERP Program & Medication Safety

Document Request

• Medication error reports for last 3 yrs• Outcome data related to medication

errors• Committee minutes - oversight of MERP 3

yrs• Adverse events since July 1, 2007

MERP Attachment A

Page 13: MERP Program & Medication Safety

MERP Facility Questionnaire

• Is there a method to address each of the “procedures and systems” so as to identify weakness or deficiencies? [Question A] Guidance:

What methodology is utilized for evaluating each procedures and systems that can contribute to medication errors

Method: procedure or processExamples; evaluation of external alerts,

medication pass observation, QAPI studies, analysis of medication error reports

MERP Attachment B

Page 14: MERP Program & Medication Safety

Procedure or System: Methodology:Evaluation frequency:

Date last completed:

Weaknesses ordeficiencies identified:

Date identified:

Prescribing: ____/____/______

Use for question B

____/____/______

Prescription order communications:

____/____/______ ____/____/______

Product labeling: ____/____/______ ____/____/______

Packaging and nomenclature:

____/____/______ ____/____/______

Compounding: ____/____/______ ____/____/______

Dispensing: ____/____/______ ____/____/______

Question A: MERP Survey Questionnaire

Page 15: MERP Program & Medication Safety

MERP Facility Questionnaire

• Has the plan been modified when weakness or deficiencies are noted to achieve the reduction of errors? [Question B] Guidance

Were weakness or deficiencies identified?If identified, was the plan modified?Was there follow-up done to assess

effectiveness of the plan modification?

Page 16: MERP Program & Medication Safety

Procedure or system:

Date identified:

Weakness identified:

Plan modification:

Date initiated:Follow-up assessment

done:

Prescribing:

____/____/______

From Question A

____/____/______

____/____/______ ____/____/______

____/____/______ ____/____/______

Prescription order communication: ____/____/______ ____/____/______

____/____/______ ____/____/______

____/____/______ ____/____/______

Question B: MERP Survey Questionnaire

Page 17: MERP Program & Medication Safety

MERP Facility Questionnaire

• Has an annual review been done to assess the effectiveness of the plan for each of the procedures and systems? Guidance

Annual review should have started 2006Methodology used to assess effectiveness

should provide objective and relevant evidence that informs policy decision makers in the evaluation and development of corrective actions

Page 18: MERP Program & Medication Safety

Procedure or system:

Annual review date (required):

Interval review date(s)

(optional):

Does the annual review demonstrate assessment

for effectiveness?Comment:

Prescribing:____/____/2006

____/____/2006____/____/2006

Yes No N/A

____/____/2007____/____/2007____/____/2007

Yes No N/A

____/____/2008____/____/2008____/____/2008

Yes No N/A

____/____/2009____/____/2009____/____/2009

Yes No N/A

____/____/2010____/____/2010____/____/2010

Yes No N/A

Question C: MERP Survey Questionnaire

Page 19: MERP Program & Medication Safety

Survey Activities

• Medication pass observation – SNF process• Inspections – ED, Surgery, ICU, Med/surgical• Clinical record review

Sample from requested records Open records – ED, ICU, Med/Surgical

• Medication error reports Sample from each of the past 3 years

• Emergency medication Crash Carts Malignant Hyperthermia

Page 20: MERP Program & Medication Safety

MERP Survey Summary January 2009 – March 2010

• 381 – Hospitals to be surveyed• 240 – Selected to be surveyed (63%)

January 1, 2009 – September 30, 2010

• 167 – Completed surveys (76%) • 145 – Noted deficiencies (87%) • 22 – In compliance (13%)

Data as of 7/22/2010

Page 21: MERP Program & Medication Safety

MERP Survey Summary

• On average three (3) different deficient practices are cited per non-compliant Statement of Deficiencies issued.

• Common deficiencies CCR 70263(c)(1) – 40% Health and Safety Code

28% - 1339.63 (e)(2) 23% - 1339.63 (e)(1) 20% - 1339.63 (e)(6)

Page 22: MERP Program & Medication Safety

Regulation/Law

• CCR Title 22 – 70263(c)(1) Must develop policies and procedures for establishment of safe and effective systems for procurement, storage, distribution, dispensing and use of drugs.

• H&S Code 1339.63(e)(1)(2)(6) Identify weakness or deficiencies that could

contribute to errors -23% Conduct an annual review to assess

effectiveness of the implementation of MERP – 28%

Include a multidisciplinary process to regularly analyze all errors – 20%

Page 23: MERP Program & Medication Safety

23

Administrative Penalties

Page 24: MERP Program & Medication Safety

Administrative Penalties

• Effective January 1, 2007 – CDPH may issue Administrative Penalties (AP) to hospitals [Health and Safety Code 1280.1]

• AP is a civil monetary penalty for a deficiency constituting an Immediate Jeopardy. Immediate Jeopardy is a situation in which the

hospital’s noncompliance with one or more requirements of licensure has caused, or is likely to cause, serious injury or death to the patient.

Page 25: MERP Program & Medication Safety

A look at the data...

• There were 82 Administrative Penalties (APs) issued between January 2007 to August 1, 2009

• These 82 AP’s contained 106 regulatory deficiencies which were sorted into regulatory groupings as listed in California Title 22 for General Acute Care Hospitals.

UCSD Pharmacy Resident Project CDPH Rotation Summer 2009

Page 26: MERP Program & Medication Safety

0123456789

101112131415161718192021222324252627282930313233 Pharmacy

Nursing

Surgery

GoverningBody

DietaryServices

Distribution of Deficiencies by Title 22 Regulatory Groupings

N= 106

33%

Pharmacy and Nursing =51.9% of all deficiencies.

18.9%

9.4% 8.5%6.6%

Page 27: MERP Program & Medication Safety

Pharmacy Regulatory Groupings

0

5

10

15

20

25

30

Number

70263(c)

70263(c)(1)

70263(f)

70263(g)(2)

70263(g)(6)

70265

70267(a)

N=3570263(C)(1)

Shall develop and implement policies and procedures for safe and effective systems for procurement, storage, distribution, dispensing and use of drugs and chemicals

26/35= 74.3%

70263(g)(2)Medications and treatments shall be administered as ordered.

4/35= 11.4%

Page 28: MERP Program & Medication Safety

28

Administrative Penalties (AP)

•Between January 1, 2007 to May 20, 2010: 146 administrative penalties issued, including:

39 issued in FY 2007-0848 issued in FY 2008-0959 issued in FY 2009-10

• Categories of APs: Medication/pharmacy related errors: 42 (28.8%) Retention of foreign object: 28 (19.2%) Patient care issues: 26 (17.8%) Patient safety: 25 (17.2%)

Page 29: MERP Program & Medication Safety

29

Administrative Penalties Issued

• APs fines $2.87 million has been collected. Quality Improvement fund

•Administrative penalties appealed: 37 14 settled or withdrawn 23 in various states of appeal process

Page 30: MERP Program & Medication Safety

Medication Safety System Vulnerabilities

• Management of High Risk Medications Fentanyl Transdermal Patch

• Provision of Emergency Medications• Safe Storage of Medications

Includes all areas listed on CDPH issued license (e.g. outpatient)

Page 31: MERP Program & Medication Safety
Page 32: MERP Program & Medication Safety

Emergency Medications

• Provision of emergency medications to ensure safe and effective use – pediatric, neonate and adult

• Adequate supplies• Competency• Malignant Hyperthermia – MHAUS.org• AFL 05-02

Page 33: MERP Program & Medication Safety
Page 34: MERP Program & Medication Safety

Safe Storage

• Recalls Board of Pharmacy - guidelines on Drug

Distribution http://www.pharmacy.ca.gov/licensing/

best_practices_recalls.pdf

• Refrigeration

Page 35: MERP Program & Medication Safety

CDPH ALERT — Check Your Medication Refrigerators

CDPH has identified a number of situations in which the storage of refrigerated medications has not protected the health and safety of patients.

The situations have involved refrigerators located on clinical units (e.g. emergency department) and in the pharmacy where the noted refrigerator temperature was outside of the acceptable range.

Refrigerator temperature shall be between 2.2° Celsius (36° Fahrenheit) and 7.7° Celsius (46° Fahrenheit) in accordance with California Code of Regulations (CCR), Title 22, Section 70263 (q)(6).

In all cases the failure to maintain an appropriate temperature range was over an extended period of time (e.g. months) and involved both elevated temperatures (greater than 8° Celsius) and lower temperatures (below 2° Celsius).

September 2009, Vol. 1 No. 7

Page 36: MERP Program & Medication Safety
Page 37: MERP Program & Medication Safety

MERP and Beyond

• Medication Safety Committee ED Order Review High Risk/High Alert Medications MERP

Page 38: MERP Program & Medication Safety

Best Practices?

“The department may work with the facility's health care community to present an annual symposium to recognize the best practices for each of the procedures and systems.”

[HSC 1339.63 (g)]

Page 39: MERP Program & Medication Safety

Thank you!